CTI BioPharma (CTIC) Updates on Pacritinib Full Clinical Hold; Dose Exploration Studies Suggested by FDA
Tweet Send to a Friend
CTI BioPharma (Nasdaq: CTIC) disclosed the following on Monday:Item 7.01 Regulation FD DisclosureOn March 14, 2016, CTI BioPharma Corp. (the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
